Immediate Impact
1 from Science/Nature 52 standout
Citing Papers
Advances and challenges in therapeutic targeting of NRF2
2023 Standout
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases
2023 Standout
Works of Robert McNeill being referenced
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
2012
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Robert McNeill | 23 | 29 | 58 | 55 | 7 | 201 | ||
| David Chaney | 5 | 4 | 153 | 73 | 7 | 240 | ||
| Sam Woolford | 5 | 12 | 5 | 22 | 9 | 260 | ||
| Jennifer Dyer | 11 | 14 | 13 | 15 | 10 | 254 | ||
| Megan Wong | 45 | 9 | 16 | 4 | 10 | 182 | ||
| Jeanne Reeve | 3 | 6 | 1 | 4 | 36 | 10 | 200 | |
| Siegfried Meryn | 15 | 20 | 1 | 72 | 3 | 10 | 224 | |
| Fatıma Adam | 6 | 11 | 19 | 37 | 12 | 264 | ||
| David Shukla | 11 | 5 | 19 | 16 | 9 | 182 | ||
| Mike Davis | 24 | 6 | 50 | 20 | 9 | 205 | ||
| Christopher E. Beaudoin | 3 | 2 | 4 | 18 | 8 | 236 |
All Works
Loading papers...